Andrew Oshaughnessy, MD
Nephrology · Fort Wayne, INNPI 1568416865
Payments from drug & device makers
Across 949 payments — averaging $1311.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$786K
- GSK$238K
- Eli Lilly$69K
- CSL Behring$38K
- Boehringer Ingelheim$36K
- AstraZeneca$27K
- plus $50K from 26 others
Across 4 payments — averaging $1146.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ardelyx, Inc.$4K
- Eli Lilly$586
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 529 | $786,418 |
| GSK | 97 | $238,466 |
| Eli Lilly | 1 | $69,442 |
| CSL Behring | 17 | $37,997 |
| Boehringer Ingelheim | 46 | $35,545 |
| AstraZeneca(2 entities) | 25 | $26,804 |
| Lilly USA, LLC | 38 | $22,948 |
| E.r. Squibb & Sons, L.L.C. | 2 | $10,700 |
| Janssen Research & Development, LLC | 1 | $4,162 |
| Ardelyx, Inc. | 7 | $4,069 |
| AbbVie | 2 | $3,542 |
| Bayer | 62 | $1,118 |
| Otsuka America Pharmaceutical, Inc. | 17 | $548 |
| Amgen(2 entities) | 24 | $513 |
| Vifor Pharma, Inc. | 15 | $491 |
| Boehringer Ingelheim International GmbH | 6 | $428 |
| Fresenius USA Marketing, Inc. | 16 | $334 |
| Mallinckrodt Hospital Products Inc. | 7 | $249 |
| Novartis | 8 | $139 |
| Travere Therapeutics, Inc. | 5 | $129 |
| Alnylam Pharmaceuticals Inc. | 1 | $121 |
| Calliditas Therapeutics US Inc. | 5 | $101 |
| Bard Peripheral Vascular, Inc. | 1 | $101 |
| Nxstage Medical, Inc. | 1 | $71 |
| OPKO Pharmaceuticals, LLC | 4 | $66 |
| Aurinia Pharma U.S., Inc. | 3 | $59 |
| Daiichi Sankyo Inc. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Novo Nordisk | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Mallinckrodt Enterprises LLC | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
How this compares
$1,244,727 in reported general payments places this provider in the 95th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Fort Wayne
- Garima GuptaFort Wayne$666K
- John DuckerFort Wayne$135K
- Melanie BarridoFort Wayne$66K
- Irfan MunirFort Wayne$5K
- Sajjad HabibFort Wayne$4K
- Kanakapura VenkatakrishnaFort Wayne$4K
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Bruce MolitorisIndianapolis$471K
- Kenneth ChoiMerrillville$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.